To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure email@example.com
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This is a copy of the slides presented at the meeting but not formally written up for the volume.
Dendrimers are routinely synthesized as tuneable nanostructures that are designed and regulated as a function of their size, shape, surface chemistry and interior void space. They are obtained with structural control approaching that of traditional biomacromolecules such as DNA/RNA or proteins and are distinguishable by their precise nanoscale scaffolding and nano-container properties. This lecture will review progress on the use of these features for both targeted diagnostic and drug delivery applications. Recent efforts have focused on the synthesis and preclinical evaluation of a multi-purpose, STARBURST® poly(amidoamine) (PAMAM) dendrimer prototype that exhibits properties suitable for use as: (i) a targeted, diagnostic MRI contrast agent (ii) and/or for controlled delivery of cancer therapies. Special emphasis will be placed on the lead candidate, namely; (core: 1,4-diaminobutane; G=4.5); [dendri-PAMAM(CO2Na)64]. This dendritic nanostructure was selected based on a very favorable nanotoxicity profile*, the expectation that it will exhibit desirable kidney excretion properties and demonstrated targeting features.*The Nanotechnology Characterization Laboratory (NCL), an affiliate of the National Cancer Institute (NCI) has studied the lead compound and found it to be extraordinarily benign and highly biocompatible.
Email your librarian or administrator to recommend adding this to your organisation's collection.